Louis Cannon

Louis Cannon, MD, a former Judith Volkman Scholar in Residence, is the President of the Cardiac and Vascular Research Center of Northern Michigan. Dr. Cannon has been repeatedly honored as one of "America’s Top Interventional Cardiologists.” He has authored hundreds of articles for medical publications and holds a vast number of medical device patents in the United States. Currently, he is a member of the Board of Directors of CardioVascular Ingenuity and Kona. Previously, he has served on the strategic advisory boards for Fortune 500 companies such as Medtronic, Abbott, Boston Scientific, Johnson and Johnson, and Covidien, as well as many early developing medical technology companies. Dr. Cannon, through BioStar Ventures, has participated in the start-up and subsequent development of a multitude of developing bio-technological, or emerging healthcare companies, and has served as the National or International Principal Investigator for landmark cardiovascular studies. Additionally, he was Chairman of the Board of AorTx, Inc., which was successfully acquired by a publicly traded company. Similarly, as BioStar was the lead investor of Setagon, later acquired by a Fortune 100 company, Dr. Cannon served as the Chairman of the Scientific Advisory Board. In 2007, Dr. Cannon assisted in performing First-In-Man percutaneous Aortic Valve procedures in Paraguay.